secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2026-07-16T20:25:02+00:00
Accession:  0001628280-26-048469
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis appoints Christopher Peetz to Board of Directors
--------------------------------------------------------

- Christopher Peetz appointed as Class III director effective July 15, 2026; term expires at 2029 annual meeting.
- Peetz is co-founder and CEO of Mirum Pharmaceuticals; brings biopharma leadership and M&A experience.
- Received initial option for 21,486 shares; eligible for prorated annual equity (~$350K) and $50K cash retainer.
- Board determined Peetz qualifies as independent under SEC and Nasdaq rules; no committee assignment yet.
- Appointment expands board from nine to ten members; no family or material transaction relationships disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000162828026048469/0001628280-26-048469-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000162828026048469/arqt-20260715.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-048469

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer